Oxford Cannabinoid Technologies Holdings plc (OCTP), the pharmaceutical company developing prescription cannabinoid medicines, has announced that all cohorts have been dosed in a phase 1 study of OCT461201.
Cannabidiol (CBD) is marketed by some suppliers as a painkiller, e.g. for osteoarthritis of the knee. Animal experiments have shown that the substance, which is extracted from the hemp plant, has an anti-inflammatory and pain-relieving effect in arthritis.
The study in the International Journal of Obesity reports that cannabis and its derivatives may influence weight and waist circumference, with different effects on body fat, suggesting potential as a therapeutic aid in obesity management.